Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights the need for real-world (RW) evidence. We conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Faith, Rifkin, Robert, Costello, Caitlin, Morgan, Gareth, Usmani, Saad, Abonour, Rafat, Palumbo, Antonio, Romanus, Dorothy, Hajek, Roman, Terpos, Evangelos, Cherepanov, Dasha, Stull, Dawn Marie, Huang, Hui, Leleu, Xavier, Berdeja, Jesus, Lee, Hans C., Weisel, Katja, Thompson, Michael, Boccadoro, Mario, Zonder, Jeffrey, Cook, Gordon, Puig, Noemi, Vela-Ojeda, Jorge, Farrelly, Eileen, Raju, Aditya, Blazer, Marlo, Chari, Ajai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357697/
https://www.ncbi.nlm.nih.gov/pubmed/33970288
http://dx.doi.org/10.1007/s00277-021-04534-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357697/
https://www.ncbi.nlm.nih.gov/pubmed/33970288
http://dx.doi.org/10.1007/s00277-021-04534-8

Ejemplares similares